HAYWARD, Calif.--(BUSINESS WIRE)--
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical
company focused on creating innovative cancer immunotherapies, today
announced the promotion of Jennifer Jarrett from Chief Business Officer
and Chief Financial Officer to Chief Operating Officer. In this new
role, Ms. Jarrett will be responsible for several key areas, including
finance, investor relations, corporate communications, business and
corporate development, strategic planning and human resources. Ms.
Jarrett will also continue to be the Company’s Chief Financial Officer.
“Since joining Arcus, Jennifer has successfully built out our finance,
investor relations and corporate communications functions and played a
central role in our fundraising and business development activities,”
said Terry Rosen, Ph.D., Chief Executive Officer at Arcus. “Jennifer’s
promotion to Chief Operating Officer reflects a recognition of her
outstanding leadership and the impact that she has had across the
breadth of Arcus’s operations to date and our company’s increasing focus
on portfolio prioritization and early commercial planning. We will
benefit greatly from Jennifer’s extensive knowledge of the commercial
landscape and the vision that she brings to the careful consideration of
the numerous opportunities and challenges associated with the
next-generation immuno-oncology agents we are advancing into and through
clinical development.”
Ms. Jarrett joined Arcus in 2017 and has over 20 years of experience in
biotechnology. Prior to joining Arcus, Ms. Jarrett was the Chief
Financial Officer of Medivation, through its acquisition by Pfizer in
September 2016; there, she was responsible for finance and accounting,
investor relations, business development and information technology.
Prior to Medivation, Ms. Jarrett spent 18 years in investment banking,
most recently as a Managing Director in Citigroup’s Health Care
Investment Banking Group, where she built and led their west coast
biotechnology investment banking practice. Ms. Jarrett also serves on
the Board of Directors of Arena Pharmaceuticals and Audentes
Therapeutics. Ms. Jarrett received her M.B.A. from Stanford Graduate
School of Business and her undergraduate degree in Economics from
Dartmouth College.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused
on creating innovative cancer immunotherapies. Arcus has several
programs targeting important immuno-oncology pathways, including a dual
adenosine receptor antagonist AB928, which will be evaluated in
combination with other agents in multiple tumor types in a Phase 1/1b
program, and an anti-PD-1 antibody, which is being evaluated in a Phase
1 trial and will be tested in combination with Arcus’s other product
candidates. Arcus’s other programs include a small molecule inhibitor of
CD73 and an anti-TIGIT antibody, both of which are in IND-enabling
studies. Arcus has extensive in-house expertise in medicinal chemistry,
immunology, biochemistry, pharmacology and structural biology. For more
information about Arcus Biosciences, please visit www.arcusbio.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements
other than statements of historical facts contained herein, including,
but not limited to, the advancement of Arcus’s pipeline, are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause Arcus’s actual
results, performance or achievements to differ significantly from those
expressed or implied. Factors that could cause or contribute to such
differences include, but are not limited to, the inherent uncertainty
associated with pharmaceutical product development and clinical trials,
changes in expected or existing competition and our limited operating
history. Risks and uncertainties facing Arcus are described more fully
in Arcus’s quarterly report on Form 10-Q for the quarter ended March 31,
2018 filed on May 9, 2018 with the SEC. You are cautioned not to place
undue reliance on the forward-looking statements, which speak only as of
the date of this press release. Arcus disclaims any obligation or
undertaking to update, supplement or revise any forward-looking
statements contained in this press release.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180612005388/en/
Arcus Biosciences
Jennifer Jarrett, 510-694-6261
jjarrett@arcusbio.com
or
Nicole
Arndt, 510-284-4728
narndt@arcusbio.com
Source: Arcus Biosciences